coronavirus (covid-19) disease. COVID-19 Disease
Conditions
Interventions
Intervention 1: Intervention group: Patients receiving 3 capsules of 500 mg per day of curcumin-piperine (manufactured by Sami Lab India) for 7 days (a total of 1500 mg of curcumin per day and 15 mg o
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Willingness to participate in the study Age 20-80years Diagnosis of Covid-19 based on clinical findings and PCR findings Gastrointestinal tract with normal function and intestinal nutrition criteria
Exclusion criteria
Exclusion criteria: Age less than 20 and more than 80 years Sensitivity to plant products such as turmeric and pepper Impossibility of intestinal feeding in the first 48 hours of admission Patients who are hospitalized in the intensive care unit for less than 48 hours. Patients who are expected to die within 12 hours of admission to the intensive care unit. Patients who do not have an indication for intestinal nutrition on the first day and are confirmed and predicted based on the diagnosis of the intensive care unit that they will not be able to receive intestinal nutrition in the future. (Nausea, persistent vomiting, ileus, intestinal obstruction, uncontrolled diarrhea (> 500 ml per day), high-output fistula (> 500 ml per day), intestinal inaccessibility, incomplete resuscitation and hemodynamic instability Patients with BMI <18.5kg / m2 admitted to the intensive care unit. Patients who receive nutritional support through complete intravenous feeding Patients with a history of underlying disease such as congenital and immune disorders, renal and hepatic insufficiency and pancreatitis.Community Verified icon Taking anticoagulants such as heparin, warfarin, aspirin, etc. Pregnancy and lactation Severe septic shock or sepsis Dissatisfaction of the patient or her legal guardian
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body temperature. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: By using clinical thermometer.;Hs-CRP. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: En Enzymatic method.;Duration of hospitalization. Timepoint: At the time of discharge from the hospital. Method of measurement: By Using the patient's medical record.;Severity and number of coughs. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Visual analogue scales (VAS) for cough.;ALT. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;AST. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;LDH. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;BUN. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;Creatinine. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;CBC. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Device analysis using cell counter device (hematology analyzer).;Albumin. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;Blood sugar. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;ESR. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic method.;NUTRIC score. Timepoint: Before and after the intervention. Method of measurement: By scoring a questionnaire including APACHE II and SOFA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGholamreza Askari
Esfahan University of Medical Sciences
Outcome results
None listed